Wolverine is a vendor name for a pre-mixed vial containing two synthetic peptides, BPC-157 and TB-500, supplied together as a single lyophilised powder. Athena lists it at 20 mg per vial, 10 mg of each, which is a 1:1 ratio. It is marketed for tendon, ligament and soft-tissue recovery, and the name is a marketing name rather than a compound name — there is no substance called "Wolverine."
| Component | Amount | What it is | Proposed role in the blend |
|---|---|---|---|
| BPC-157 (Body Protection Compound) | 10 mg | Synthetic 15-amino-acid partial sequence of a protein found in human gastric juice | Angiogenesis and nitric oxide signalling; connective-tissue and gastrointestinal repair |
| TB-500 (Thymosin Beta-4 Fragment) | 10 mg | Synthetic 7-amino-acid fragment (Ac-LKKTETQ) of the 43-amino-acid protein thymosin beta-4 | Actin sequestration, cell migration and tissue remodelling |
Because both peptides sit in one vial, a draw delivers them in the proportion the vial was filled at and no other. A 0.5 mg draw is 0.25 mg of BPC-157 and 0.25 mg of TB-500. Neither can be increased, reduced or stopped without doing the same to the other, which is the main practical difference between this vial and the two compounds bought separately. The individual profiles for BPC-157 and TB-500 set out what is known about each on its own.
The rationale for pairing them is that they are associated with different repair mechanisms — vascular and cytoprotective on one side, cytoskeletal and migratory on the other — so combining them might do more than either alone. That rationale is plausible and it is also entirely untested. No published study examines these two peptides in combination, in any model system. The word "synergy" is a specific pharmacological claim requiring experimental validation, and none exists here.
The component evidence is thinner than the marketing implies. Both peptides have a substantial preclinical literature, almost all of it in rodents. Neither has a published human study establishing a subcutaneous amount, schedule or duration; the handful of human BPC-157 reports used intravenous, intra-articular and intravesical routes, and the human thymosin beta-4 work used the full protein rather than the TB-500 fragment. Both are classified by the FDA as Category 2 bulk drug substances — identified as presenting significant safety risks and prohibited from compounding for human use.
| Weeks | Dosage | Syringe units (U-100) |
|---|---|---|
| Weeks 1–2 | 0.25 mg | 3.75 units0.04 mL |
| Weeks 3–8 | 0.5 mg | 7.5 units0.07 mL |
FrequencyOnce daily, subcutaneous, as a four-to-eight-week course followed by a break.
For review — no human dosing exists for this blend. Wolverine has never been studied as a combination, so there is no established amount and no established frequency; the two rows in the chart are the amounts circulated for it, given as the total the vial delivers. The concentration strip above the chart is calculated from the vial and water volume and is correct.
Unverified — no study of the blend establishes a course length or a frequency, and no published human study establishes a subcutaneous schedule for either component on its own.
The amount charted is the total the vial delivers, not a figure for either peptide on its own. Athena lists the vial as 10 mg of BPC-157 and 10 mg of TB-500 — 20 mg in total at a 1:1 ratio — so a 0.5 mg draw carries 0.25 mg of each, in a proportion fixed by the vial rather than chosen. The two rows are the two amounts circulated for this blend, 250 mcg and 500 mcg of total blend daily; this page puts the lower one first because starting low is the conservative reading, not because a study sequenced them that way. Neither figure comes from a trial, and the four-to-eight-week course is the circulated structure rather than a finding. Made up with 3 mL the vial is about 6.7 mg/mL, which puts the two rows at 3.75 and 7.5 units — both small draws, well inside a 50-unit syringe. One practical consequence: at these amounts a single 20 mg vial holds forty to eighty daily doses, far more than the roughly four weeks a reconstituted vial keeps for under refrigeration, so most of a vial made up all at once is not usable. Because the two peptides are fixed in one vial they cannot be titrated separately the way each was studied on its own.
What this evidence establishes. No human dosing exists for the Wolverine blend. It has never been studied as a combination — there is no trial of the blend, no validated ratio and no established frequency. Nor does the component literature supply one: no published human study establishes a subcutaneous amount, schedule or duration for BPC-157 or for TB-500, and the handful of human reports that exist for BPC-157 used other routes. Because a blend is supplied at a fixed ratio in a single vial, the amount of each component is set by the vial rather than chosen.
For educational and laboratory research purposes only. It does not provide medical advice, dosing recommendations, or instructions for human or veterinary use. Syringe units assume a U-100 syringe, on which 1 mL is 100 units and a 50-unit syringe holds 0.5 mL.
These mechanisms come from preclinical research on the individual peptides. None of it was generated with the two co-administered.
Modulates the nitric oxide system and promotes blood-vessel formation; protects gastrointestinal mucosa. Rodent models of tendon, ligament and gut injury. FDA Category 2. (Sikiric et al.)
Sequesters G-actin and promotes cell migration toward injury sites. The fragment is the actin-binding region of thymosin beta-4, not the whole protein. FDA Category 2. WADA prohibited. (Goldstein et al.)
One draw delivers both at the vial's proportion. Neither component can be titrated, paused or withdrawn independently of the other.
No published research examines these two peptides together. Whether the effects add, do nothing, or interfere is unknown and untested.
The stability of two peptides stored and reconstituted in the same vial has not been validated in published research.
Subcutaneous injection after reconstitution with bacteriostatic water. The circulated amounts assume that route; no human study establishes it for either peptide.
There is no safety data on this combination. What follows is drawn from the two component literatures, which are themselves almost entirely preclinical. Interactions between the two peptides are uncharacterised.
| Concern | Risk level | Rationale |
|---|---|---|
| Active cancer or malignancy | HIGH | Both components are associated with angiogenesis and cell migration in preclinical models. Both mechanisms could theoretically support tumour growth and vascularisation. |
| FDA Category 2 classification (both components) | HIGH (regulatory) | BPC-157 and TB-500 are both listed by the FDA as presenting significant safety risks and are prohibited from compounding for human use. |
| Pregnancy or breastfeeding | HIGH | No reproductive safety data exists for either component or the combination. Standard exclusion for unstudied compounds. |
| Competitive athletes subject to testing | HIGH (sanction) | Both components appear on the WADA Prohibited List under S0, banned at all times, in and out of competition. Validated detection assays for TB-500 have existed since 2012. |
| Drug interactions | UNKNOWN | No interaction study exists for either peptide, in combination or with any medicine. Pharmacokinetic and pharmacodynamic interactions are uncharacterised. |
| Fixed ratio, no independent titration | MODERATE (practical) | A single draw delivers both peptides. Reducing exposure to one necessarily reduces the other, and an adverse response cannot be attributed to a component or managed by adjusting it. |
| Co-formulation stability | UNKNOWN | Degradation kinetics and possible interactions between two peptides stored together, dry and in solution, have not been validated in published research. |
| Vial size against reconstituted shelf life | MODERATE (practical) | At the amounts circulated for this blend a 20 mg vial holds forty to eighty daily doses, well beyond the roughly four weeks a reconstituted vial is generally held to keep for under refrigeration. |
| Human safety data (individual components) | LIMITED TO ABSENT | No published human study establishes a subcutaneous amount, schedule or duration for either peptide. The small BPC-157 human reports used other routes; the human thymosin beta-4 work used the full protein rather than the TB-500 fragment. |
| Human safety data (combination) | ABSENT | No published study of any kind examines BPC-157 and TB-500 co-administered, in any model system. |
| Quality control and vendor variation | VARIABLE | Purity, sterility and the accuracy of the stated 10 + 10 mg fill vary by supplier. A blend adds a second peptide's assay to what a certificate of analysis has to establish. |
FDA: Neither component is approved for any therapeutic use. Both are listed as Category 2 bulk drug substances, meaning the agency has identified significant safety risks and prohibited their compounding for human use. The blend has no separate regulatory status of its own.
WADA: Both components fall under S0 (Non-Approved Substances) on the Prohibited List, banned at all times, in and out of competition.
DEA: Neither component is a scheduled substance.
Key distinction: A blend is not evidence of a combination. Pre-mixing two peptides makes them easier to inject together; it does not generate data about what they do together, and it removes the ability to vary them independently. On the evidence available, Wolverine is two under-studied compounds in one vial rather than a studied product.
This profile is for educational and research purposes only. It is not medical advice, and nothing on it is a protocol, a recommendation, or an instruction for use in a person or an animal.
Athena Peptides Education does not prescribe, sell, or recommend any compound. Compounds discussed here are for laboratory research only and are not for human consumption. Always consult a qualified physician before making any decision about your health.